AI SummarySummary: Immunotherapy has shown promise in treating specific types of prostate cancer by slowing down disease progression in men with certain genetic characteristics. In a recent study, the progression of the disease was delayed by 33 months in these individuals.New research has shown that immunotherapy can be effective in treating prostate cancer in men… Continue reading Immunotherapy shows promise for men with specific types of prostate cancer
Category: Oncology
Study links neighborhood environment to prostate cancer risk in men with West African genetic ancestry
AI SummaryThe study explores the association between West African genetic ancestry and prostate cancer risk in men living in different neighborhood environments. It suggests that neighborhood disadvantage may impact the relationship between genetic ancestry and prostate cancer risk. This research highlights the importance of considering both genetic and environmental factors in understanding health disparities.West African… Continue reading Study links neighborhood environment to prostate cancer risk in men with West African genetic ancestry
Smoking prevalence and association with sociodemographic variables in cancer clinical trial participants
AI SummaryThis study examines smoking prevalence and its association with sociodemographic variables in cancer clinical trial participants. Nearly half of the 4326 patients enrolled in 29 trials reported ever smoking, with one in six reporting current or recent smoking. Factors associated with smoking included male gender, older age, Medicaid or no insurance, high socioeconomic deprivation,… Continue reading Smoking prevalence and association with sociodemographic variables in cancer clinical trial participants
Janus Henderson Offers Money Market Fund to Support the American Cancer Society’s Efforts in Advocacy, Research & Patient Support
Janus Henderson will donate an amount equal to half of its management fees for all assets under management from the Fund
NIH study links neighborhood environment to prostate cancer risk in men with West African genetic ancestry
AI SummarySummary: The study highlights that living in a disadvantaged neighborhood increases the risk of prostate cancer in men with West African genetic ancestry. Chronic stress from various sources like racial profiling and housing discrimination is believed to contribute to this heightened risk.A new study suggests, for men with West African genetic ancestry, living in… Continue reading NIH study links neighborhood environment to prostate cancer risk in men with West African genetic ancestry
Immunotherapy after surgery helps people with high-risk bladder cancer live cancer-free longer
AI SummaryThis article discusses the results of an NCI trial indicating that administering pembrolizumab to patients after surgery for high-risk muscle invasive bladder cancer can double the median length of time they remain cancer-free compared to observation alone after surgery. This finding underscores the potential benefits of immunotherapy in treating high-risk bladder cancer patients.An NCI… Continue reading Immunotherapy after surgery helps people with high-risk bladder cancer live cancer-free longer
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
AI SummaryIn this study, the safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, is examined in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC). The drug targets the androgen receptor via a unique mechanism of AR degradation and antagonism. The study, known as CC-94676-PCA-001 (NCT04428788), is a… Continue reading Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
Ipilimumab with Nivolumab in molecular-Selected patients with castration-resistant PRostate cancer: primary analysis of the Phase 2 INSPIRE trial
AI SummaryThis study focuses on the use of a combination of immune checkpoint inhibitors, Ipilimumab and Nivolumab, in molecularly-selected patients with castration-resistant prostate cancer. The aim is to investigate the efficacy and safety of this treatment approach in a subset of patients who display a more immunogenic profile. The results of this study could provide… Continue reading Ipilimumab with Nivolumab in molecular-Selected patients with castration-resistant PRostate cancer: primary analysis of the Phase 2 INSPIRE trial
Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY
AI SummaryThe article discusses the use of circulating-tumor DNA (ctDNA)-based molecular residual disease (MRD) detection in patients with colorectal liver metastases (CLM). The study aims to explore the survival benefit of adjuvant chemotherapy (ACT) in this patient population after surgical resection. This research could potentially provide valuable insights into risk-stratification and treatment options for individuals… Continue reading Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY
The global epidemic of early-onset cancer: Nature, nurture, or both?
AI SummaryThe article discusses the rising incidence of early-onset cancer (EOC) diagnosed under the age of 50 globally. This trend is not limited to colorectal cancer (CRC) but also includes various other types of cancer such as bile duct, breast, bone marrow, esophagus, gallbladder, head and neck, kidney, liver, stomach, pancreas, and uterine corpus. The… Continue reading The global epidemic of early-onset cancer: Nature, nurture, or both?